Prices are closing data as of 2026-11-04, not real-time quotes. HK P/E and P/B multiples come from Eastmoney HK key statistics. Metric definitions: P/E, P/B, ROE.
Want the full AI research report for KEYMED BIO-B?
This free page compiles public filings, financial ratios and risk screening. Generate a full research report to add business moat & competition, valuation scenarios, catalysts and bull/bear cases right at this URL.
New users who sign up free and verify their email receive 2 free credits for research reports or professional valuation.
10-Year FinancialsFY2019–2025
Financial statements are reported in CNY, while share price and market cap are quoted in HKD.
Key Multi-Year Facts
- Net income was negative in FY2019, FY2020, FY2021, FY2022, FY2023, FY2024, FY2025.
Latest 5 Fiscal Years
| Fiscal Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue (CNY B) | 0.11 | 0.10 | 0.35 | 0.43 | 0.72 |
| YoY | — | -9.3% | 253.9% | 20.9% | 67.3% |
| Net Income (CNY B) | -3.89 | -0.31 | -0.36 | -0.52 | -0.52 |
| Operating Cash Flow (CNY B) | -0.21 | -0.40 | -0.30 | -0.79 | -0.71 |
| ROE | -106.5% | -8.8% | -11.4% | -18.9% | -19.9% |
| Gross Margin | 84.4% | 97.4% | 89.6% | 97.2% | 87.7% |
| Net Margin | -3525.3% | -307.9% | -101.5% | -120.3% | -73.0% |
| Debt-to-Assets | 7.3% | 15.1% | 23.1% | 34.3% | 34.2% |
Show all 7 fiscal years
| Fiscal Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue (CNY B) | — | 0.00 | 0.11 | 0.10 | 0.35 | 0.43 | 0.72 |
| YoY | — | — | — | -9.3% | 253.9% | 20.9% | 67.3% |
| Net Income (CNY B) | -0.17 | -0.82 | -3.89 | -0.31 | -0.36 | -0.52 | -0.52 |
| Operating Cash Flow (CNY B) | -0.07 | -0.12 | -0.21 | -0.40 | -0.30 | -0.79 | -0.71 |
| ROE | — | — | -106.5% | -8.8% | -11.4% | -18.9% | -19.9% |
| Gross Margin | — | — | 84.4% | 97.4% | 89.6% | 97.2% | 87.7% |
| Net Margin | — | — | -3525.3% | -307.9% | -101.5% | -120.3% | -73.0% |
| Debt-to-Assets | — | 306.6% | 7.3% | 15.1% | 23.1% | 34.3% | 34.2% |
Fiscal years follow the period-end calendar year (hover headers for period-end dates). ROE uses average beginning/ending equity. Source: HKEX / Eastmoney financial statements, compiled mechanically without AI. Official filings
Risk ChecklistAs of 2026-11-05
Rules-based screening using HK financial statements and HKEX announcement categories (no AI opinions).
Items Flagged for Review
- Alert
-
Alert
Net LossesGoing Concern
FY2025 (2025-12-31) CN¥-0.52B, FY2024 (2024-12-31) CN¥-0.52B
FY2025 (ended 2025-12-31)
An "Alert" or "Watch" item flags a number that merits verification in primary filings, not a sell signal.
Dividends
No dividends paid over the trailing 12 months.
Figures are gross HKD per share before applicable withholding or Stock Connect dividend taxes.
More data: All research reports · Sector leaders · Market hours & holidays.
Compiled mechanically from public filings and market quotes (data as of 2026-11-05). For informational purposes only, not investment advice.